An observational study in Lung Cancer - Non Small Cell, sponsored by Hongquan Xing. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Hongquan Xing · Observational
This study was based on public use data from the SEER database. The study did not require informed consent from the SEER registered cases, and the authors obtained Limited-Use Data Agreements from SEER.
This study utilized publicly available data from the SEER (Surveillance, Epidemiology, and End Results) database, which is a comprehensive source of information on cancer statistics in the United States. The authors did not need to obtain informed consent from individuals whose cases are registered in the SEER database because the data is anonymized and is meant for public use. Instead, the authors acquired Limited-Use Data Agreements with SEER, which are legal contracts that allow researchers to access and use specific datasets under certain conditions while ensuring that the privacy of the individuals in the database is maintained. This agreement outlines the terms of data use, ensuring that the researchers adhere to guidelines for the ethical handling of data while still enabling them to conduct their research.
6,645 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,665 are open to participants now.
This study's enrollment of 1,776 is above the median of 164 across 974 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Hongquan Xing is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients with metastatic non-small cell neuroendocrine tumors
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Surgery
Overall survival
Overall survival refers to the duration of time from the start of diagnosis until death from any cause. It is a common endpoint used in clinical trials and medical research, particularly in oncology, to measure the effectiveness of a treatment or intervention. Overall survival provides a comprehensive picture of how well patients are doing and is often expressed as a percentage or a median time (e.g., the median overall survival time).
Time frame: The estimated time period for assessing events was January 2000 through December 2021. It is the time from random assignment to death from any cause (last follow-up for lost patients; end of follow-up for patients still alive at the end of the study).
No study locations are listed for this record.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →
Hongquan Xing